Ardent Health
ARDT
10.88
+0.20
+1.87%
Ardent Health
US · ARDT
#2983 by market cap
Listed 2024
10.88
+0.20
+1.87%
Live - 5344 symbols - heartbeat 80s ago
· 2026-10-08 07:59
Pre-market
11.00
+1.10%
After-hours
10.88
0.00%
Overnight
10.75
-1.19%
- Market cap
- 1.53B
- P/E (TTM)i
- 19.78
- P/Bi
- 1.14
- EPSi
- 0.96
- Div yieldi
- 0.00%
- 52W posi
- 41%
Reader sentiment
Are you bullish or bearish on ARDT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.02, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +6.01% YoY
Margins
- Gross margin
- 40.85%
- Operating margin
- 5.15%
- Net margin
- 2.15%
Key ratios & quality
- Enterprise valuei
- 1.98B
- Altman Z-Scorei
- 2.02
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2016 | 2017 | 2018 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.11B | 3.00B | 4.08B | 4.87B | 5.13B | 5.41B | 5.97B | 6.32B |
| Gross profit | 706.27M | 1.03B | 1.36B | 1.65B | 1.76B | 2.03B | 2.40B | 2.58B |
| Selling & admin expenses | 400.75M | 582.55M | 728.18M | 837.97M | 960.00M | 1.22B | 1.35B | 1.46B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 64.27M | 121.77M | 149.76M | 436.56M | 217.03M | 224.31M | 405.76M | 325.58M |
| Pretax profit | 44.37M | 50.64M | -6.92M | 295.89M | 311.48M | 151.61M | 363.06M | 286.36M |
| Tax | 8.02M | 49.87M | 15.95M | 51.31M | 46.11M | 22.64M | 63.35M | 56.22M |
| Net profit | 36.35M | 774.00K | -22.87M | 244.58M | 265.37M | 128.98M | 299.71M | 230.14M |
| Basic EPS | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 1 |
| Diluted EPS | 0.10 | -0.25 | -0.49 | 1.09 | 1.34 | 0.38 | 1.58 | 0.96 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.50B | 1.65B | 1.58B | 1.61B | 1.60B | 1.62B |
| Gross profit | 580.73M | 702.94M | 623.90M | 676.16M | 671.89M | 666.44M |
| Selling & admin expenses | 346.67M | 362.66M | 369.58M | 376.24M | 382.84M | 394.49M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 67.09M | 137.28M | 16.46M | 104.75M | 80.91M | 55.77M |
| Pretax profit | 74.20M | 121.99M | -2.20M | 92.37M | 74.59M | 43.20M |
| Tax | 15.23M | 26.29M | -3.41M | 18.11M | 16.10M | 8.51M |
| Net profit | 58.97M | 95.70M | 1.21M | 74.26M | 58.49M | 34.69M |
| Basic EPS | 0 | 1 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.29 | 0.52 | -0.17 | 0.31 | 0.28 | 0.12 |
Balance sheet
| Line item | 2016 | 2017 | 2018 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 471.15M | 736.42M | 838.09M | -- | 1.41B | 1.62B | 1.83B | 2.06B |
| Cash & ST investments | 92.61M | 71.96M | 59.66M | -- | 456.12M | 437.58M | 556.79M | 709.60M |
| Inventory | 47.10M | 84.16M | 84.81M | -- | 107.15M | 105.49M | 115.09M | 118.59M |
| Total assets | 1.09B | 2.37B | 2.72B | -- | 4.48B | 4.73B | 4.96B | 5.29B |
| Total current liabilities | 328.14M | 507.35M | 555.22M | -- | 808.60M | 994.10M | 945.42M | 1.05B |
| Short-term debt | 7.67M | 16.88M | 8.96M | -- | 58.42M | 61.03M | 55.62M | 76.94M |
| Long-term debt | 232.70M | 935.81M | 1.25B | -- | 1.16B | 1.17B | 1.09B | 1.08B |
| Total liabilities | 689,356,000.00 | 1,614,245,000.00 | 1,964,821,000.00 | -- | 3,428,538,000.00 | 3,649,242,000.00 | 3,433,743,000.00 | 3,605,244,000.00 |
| Total equity | 396.01M | 760.28M | 759.12M | -- | 1.05B | 1.08B | 1.52B | 1.68B |
| Retained earnings | -- | -- | -- | -- | -- | -- | 365.80M | 501.61M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.76B | 1.88B | 1.96B | 2.06B | 2.02B | 2.05B |
| Cash & ST investments | 495.04M | 540.63M | 609.44M | 709.60M | 609.69M | 724.48M |
| Inventory | 120.36M | 118.40M | 121.59M | 118.59M | 119.84M | 116.02M |
| Total assets | 4.91B | 5.03B | 5.15B | 5.29B | 5.25B | 5.28B |
| Total current liabilities | 830.14M | 880.87M | 943.15M | 1.05B | 951.48M | 976.32M |
| Short-term debt | 17.76M | 19.33M | 19.34M | 76.94M | 37.64M | 28.57M |
| Long-term debt | 1.09B | 1.09B | 1.09B | 1.08B | 1.07B | 1.07B |
| Total liabilities | 3,346,781,000.00 | 3,380,879,000.00 | 3,522,526,000.00 | 3,605,244,000.00 | 3,521,608,000.00 | 3,538,674,000.00 |
| Total equity | 1.56B | 1.65B | 1.63B | 1.68B | 1.73B | 1.74B |
| Retained earnings | 407.18M | 480.13M | 456.65M | 501.61M | 541.46M | 558.36M |
Cash flow
| Line item | 2016 | 2017 | 2018 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 85.78M | 119.47M | 159.59M | 146.91M | -38.36M | 221.70M | 315.03M | 470.51M |
| Depreciation & amortization | 71.51M | 109.53M | 143.19M | 137.20M | 138.17M | 140.84M | 146.29M | 155.70M |
| Free cash flow | 5.27M | -2.06M | -1.07M | 7.91M | -189.47M | 84.29M | 127.52M | 258.61M |
| Dividends paid | -- | -- | -- | -62.13M | -174.81M | -- | -- | -- |
| Stock buybacks / issuance | 0 | 143.94M | 99.12M | -- | 0 | 0 | 208.66M | 0 |
| Ending cash balance | 92.61M | 71.96M | 59.66M | 718.24M | 456.12M | 437.58M | 556.79M | 709.60M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -24.79M | 117.49M | 154.37M | 223.44M | -60.22M | 196.74M |
| Depreciation & amortization | 36.20M | 39.31M | 39.16M | 41.04M | 42.99M | 41.34M |
| Free cash flow | -47.70M | 71.29M | 95.57M | 139.44M | -88.31M | 158.06M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 0 | -- | -- |
| Ending cash balance | 495.04M | 540.63M | 609.44M | 709.60M | 609.69M | 724.48M |
Returns & efficiency
| Line item | 2016 | 2017 | 2018 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 5.48 | -44.41 | -18.35 | -- | 29.56 | 7.68 | 23.34 | 11.23 |
| ROA %i | 1.35 | -8.27 | -2.72 | -- | 4.22 | 1.09 | 4.34 | 2.65 |
| ROIC %i | 7.23 | -5.42 | 1.91 | -- | 8.55 | 3.48 | 8.16 | 5.13 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 3.39 | -0.46 | 2.49 | 8.00 | 7.67 | 3.87 | 7.18 | 5.40 |
| FCF / sales %i | 0.25 | -- | -- | 0.16 | -- | 1.56 | 2.14 | 4.09 |
| Current ratioi | 1.44 | 1.45 | 1.51 | -- | 1.74 | 1.63 | 1.94 | 1.97 |
| Quick ratioi | 1.08 | 1.04 | 1.06 | -- | 1.31 | 1.22 | 1.37 | 1.33 |
| Debt / assetsi | 22.15 | 40.12 | 46.29 | -- | 53.33 | 50.65 | 46.05 | 43.82 |
| LT debt / equityi | 87.31 | 247.75 | 330.38 | -- | 364.59 | 348.13 | 196.80 | 174.01 |
| Interest coveragei | 2.65 | -0.16 | 0.94 | 4.15 | 4.80 | 3.20 | 6.54 | 6.19 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 6.12 | 11.30 | 5.82 | 7.00 | 7.23 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | 10.89 | -10.42 |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | 152.66 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 21.57 | 25.56 | 18.28 | 11.23 | 10.69 | 6.01 |
| ROA %i | 4.69 | 5.29 | 4.12 | 2.65 | 2.64 | 1.52 |
| ROIC %i | 8.31 | 9.25 | 7.42 | 5.13 | 5.00 | 3.35 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 7.32 | 7.70 | 6.60 | 5.40 | 5.29 | 4.04 |
| FCF / sales %i | 1.96 | 1.74 | 2.49 | 4.09 | 3.39 | 4.76 |
| Current ratioi | 2.12 | 2.13 | 2.08 | 1.97 | 2.12 | 2.10 |
| Quick ratioi | 1.53 | 1.47 | 1.42 | 1.33 | 1.36 | 1.45 |
| Debt / assetsi | 46.35 | 45.09 | 44.15 | 43.82 | 43.51 | 42.92 |
| LT debt / equityi | 192.19 | 179.13 | 182.22 | 174.01 | 168.17 | 165.69 |
| Interest coveragei | 7.29 | 8.37 | 7.41 | 6.19 | 6.39 | 5.07 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Other managed care is the largest reported line at 42.44% of revenue, across 5 reported segments.
- No single line clears half of revenue; Medicare is next at 40.16%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Other managed care42.44%
Medicare40.16%
Medicaid9.84%
Self-pay and other5.93%
Other revenue1.63%
Quote time 2026-10-08 07:59:55 · For reference only, not investment advice and not tailored to your situation.